181 related articles for article (PubMed ID: 27070904)
1. Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review.
Rahal AK; Badgett RG; Hoffman RM
PLoS One; 2016; 11(4):e0153417. PubMed ID: 27070904
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
3. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
[TBL] [Abstract][Full Text] [Related]
4. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
Ilic D
Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
7. ERSPC, PLCO studies and critique of cochrane review 2013.
Schröder FH
Recent Results Cancer Res; 2014; 202():59-63. PubMed ID: 24531778
[TBL] [Abstract][Full Text] [Related]
8. Screening for prostate cancer: an updated Cochrane systematic review.
Ilic D; O'Connor D; Green S; Wilt TJ
BJU Int; 2011 Mar; 107(6):882-91. PubMed ID: 21392207
[TBL] [Abstract][Full Text] [Related]
9. PSA-based screening for prostate cancer. Too many adverse effects.
Prescrire Int; 2012 Sep; 21(130):215-7. PubMed ID: 23016259
[TBL] [Abstract][Full Text] [Related]
10. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
La Rochelle J; Amling CL
Curr Urol Rep; 2010 May; 11(3):198-201. PubMed ID: 20425627
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
Grubb RL; Pinsky PF; Greenlee RT; Izmirlian G; Miller AB; Hickey TP; Riley TL; Mabie JE; Levin DL; Chia D; Kramer BS; Reding DJ; Church TR; Yokochi LA; Kvale PA; Weissfeld JL; Urban DA; Buys SS; Gelmann EP; Ragard LR; Crawford ED; Prorok PC; Gohagan JK; Berg CD; Andriole GL
BJU Int; 2008 Dec; 102(11):1524-30. PubMed ID: 19035857
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
[TBL] [Abstract][Full Text] [Related]
18. The current state of prostate-specific antigen testing.
Lewis R; Hornberger B
JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
